What's com­ing? Paz­dur, Marks and Wood­cock dis­cuss FDA changes

Three of the FDA’s di­rec­tors — Richard Paz­dur, Pe­ter Marks and Janet Wood­cock — took the stage Wednes­day at Pre­vi­sion Pol­i­cy’s Bio­phar­ma Con­gress to dis­cuss all things FDA: from why the agency is viewed more pos­i­tive­ly now than in the past to what needs to hap­pen in each of their cen­ters.

CDER di­rec­tor Wood­cock said that the dif­fer­ence be­tween years past, when FDA was viewed neg­a­tive­ly, and now is that there has been a sort of sci­en­tif­ic rev­o­lu­tion, with bi­ol­o­gy be­ing har­nessed in nov­el ways and in­vest­ments at NIH pay­ing off.

Richard Paz­dur

On­col­o­gy Cen­ter of Ex­cel­lence di­rec­tor Paz­dur al­so not­ed the tremen­dous growth in un­der­stand­ing dis­eases and in the im­munol­o­gy of can­cer.

“One part of the piece in on­col­o­gy is that our staff has em­braced these changes,” he said, not­ing they’re “not just bean coun­ters for sur­vival da­ta” but have got­ten in­volved in the sci­ence of on­col­o­gy. The staff are part­ners in the process rather than just tick­ing box­es, he said.

And Marks, di­rec­tor of the Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search, ex­plained how the idea of screen­ing li­braries of com­pounds has gone out the win­dow, while nowa­days it’s more about ra­tio­nal drug de­vel­op­ment – “and gene ther­a­py is the epit­o­me of that.”

On the top­ic of gene ther­a­py, Marks not­ed there are now 700 in­ves­ti­ga­tion­al new drug ap­pli­ca­tions be­fore FDA. But com­pare that with cell ther­a­pies, he said, not­ing a gray mar­ket of un­proven treat­ments, which in some cas­es are noth­ing bet­ter than bad­ly man­u­fac­tured snake-oil that don’t con­tain live cells. He al­so said the use of un­ap­proved stem cell ther­a­pies around the coun­try is a sur­ro­gate mark­er for how Right to Try may play out. FDA doesn’t usu­al­ly learn about what is go­ing on un­til some­thing re­al­ly bad hap­pens, Marks added.

On the prospects of what’s to come at FDA, Wood­cock not­ed the re­al-time re­view pi­lot in the On­col­o­gy Cen­ter of Ex­cel­lence, which re­views parts of a sub­mis­sion be­fore the en­tire ap­pli­ca­tion is sub­mit­ted, is “fore­shad­ow­ing some­thing big­ger.” But she al­so ex­plained how the speed of re­views does not re­al­ly in­flu­ence the re­sults, say­ing: “what has changed is the cost of these drugs, and it’s changed the de­bate be­cause of val­ue.”

Nowa­days and mov­ing in­to the fu­ture, there’s a so­ci­etal ben­e­fit and harm dis­cus­sion that im­plic­it­ly in­vokes “trade-offs in val­ue – that’s the new de­bate we’re hav­ing – too fast and too slow is re­al­ly not the is­sue.”

For Marks, the biggest prob­lem mov­ing for­ward for gene ther­a­pies is the quan­tum leap need­ed in man­u­fac­tur­ing and to ap­ply­ing the tech­niques be­yond just rare dis­eases. “We need to do the kind of trans­for­ma­tion Steve Jobs did for dig­i­tal,” with man­u­fac­tur­ing gene ther­a­pies. He al­so not­ed FDA is “very le­nient” about some of its man­u­fac­tur­ing stan­dards for get­ting gene ther­a­pies in­to Phase 1 tri­als, but scal­ing up the man­u­fac­tur­ing is what’s dif­fi­cult.

Mov­ing in­to the fu­ture leg­isla­tive­ly, Wood­cock said she’s in­ter­est­ed in leg­is­la­tion on gener­ic drug la­bel­ing. “We have to clean up the ar­ma­men­tar­i­um so it doesn’t get out of date,” she said. She fur­ther not­ed FDA is work­ing with Con­gress on over-the-counter  drug re­forms, which is the ba­sis for the Of­fice of New Drug mod­ern­iza­tion. “If we don’t get the OTC re­form, we’ll have to pull back on the OND re­forms,” she said.


Im­age: Janet Wood­cock

First pub­lished here. reg­u­la­to­ry fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email news@raps.org for more in­for­ma­tion.

Author

Zachary Brennan

managing editor, RAPS

[via AP Images]

Pur­due threat­ens to walk away from set­tle­ment, asks to pay em­ploy­ees mil­lions in bonus­es

There are two updates on the lawsuit against Purdue Pharma over its role in fueling the opioid epidemic, as the Sackler family threatens to walk away from their pledge to pay out $3 billion if a bankruptcy judge does not stop outstanding state lawsuits against them. At the same time, the company has asked permission to pay millions in bonuses to select employees.

Purdue filed for chapter 11 bankruptcy this week as part of its signed resolution to over 2,000 lawsuits. The deal would see the Sackler family that owns Purdue give $3 billion from their personal wealth and the company turned into a trust committed to curbing and reversing overdoses.

Aerial view of Genentech's campus in South San Francisco [Credit: Getty]

Genen­tech sub­mits a plan to near­ly dou­ble its South San Fran­cis­co foot­print

The sign is still there, a quaint reminder of whitewashed concrete not 5 miles from Genentech’s sprawling, chrome-and-glass campus: South Francisco The Industrial City. 

The city keeps the old sign, first erected in 1923, as a tourist site and a kind of civic memento to the days it packed meat, milled lumber and burned enough steel to earn the moniker “Smokestack of the Peninsula.” But the real indication of where you are and how much has changed both in San Francisco and in the global economy since a couple researchers and investors rented out an empty warehouse 40 years ago comes in a far smaller blue sign, resembling a Rotary Club post, off the highway: South San Francisco, The Birthplace of Biotech.

As Nas­daq en­rolls the fi­nal batch of 2019 IPOs, how have the num­bers com­pared to past years?

IGM Biosciences’ upsized IPO haul, coming after SpringWorks’ sizable public debut, has revved up some momentum for the last rush of biotech IPOs in 2019.

With 39 new listings on the books and roughly two more months to go before winding down, Nasdaq’s head of healthcare listings Jordan Saxe sees the exchange marking 50 to 60 biopharma IPOs for the year.

“December 15 is usually the last possible day that companies will price,” he said, as companies get ready for business talks at the annual JP Morgan Healthcare Conference in January.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,000+ biopharma pros reading Endpoints daily — and it's free.

A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about it

Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,000+ biopharma pros reading Endpoints daily — and it's free.

David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects. The emergence of immunotherapy — a ferocious new titan in oncologist’s toolbox — takes the brakes off the immune system to kill cancer cells with remarkable success in some cases, but the approach is not always effective. What makes certain forms of cancer so resilient? Scientists may have finally pieced together a tantalizing piece of the puzzle, and a new biotech is banking on a new approach to fill the gap.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,000+ biopharma pros reading Endpoints daily — and it's free.

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While Novartis painstakingly works to mop up the stench of the data manipulation scandal associated with its expensive gene therapy for spinal muscular atrophy (SMA) Zolgensma— rival Biogen is attempting to expand the use of its SMA therapy, Spinraza. 

The US drugmaker $BIIB secured US approval for Spinraza for use in the often fatal genetic disease in 2016. The approval covered a broad range of patients with infantile-onset (most likely to develop Type 1) SMA. 

Jason Kelly. Mike Blake/Reuters via Adobe

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

Ginkgo Bioworks is on a roll. Days after publicizing a plan to nurture new startups via partnerships with accelerators Y Combinator and Petri, the Boston biotech says it has raised another $290 million for its cell programming platform to reach further and wider.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,000+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Speak­er Nan­cy Pelosi to un­veil bill for fed­er­al­ly ne­go­ti­at­ed drug prices

After months of buzz from both sides of the aisle, Speaker Nancy Pelosi will today introduce her plan to allow the federal government to negotiate prices for 250 prescription drugs, setting up a showdown with a pharmaceutical industry working overtime to prevent it.

The need to limit drug prices is a rare point of agreement between President Trump and Democrats, although the president has yet to comment on the proposal and will likely face pressure to back a more conservative option or no bill at all. Republican Senator Chuck Grassley is reportedly lobbying his fellow party members on a more modest proposal he negotiated with Democratic Senator Ron Wyden in July.

Jeff Kindler's Cen­trex­ion re­news bid to make pub­lic de­but

Jeffrey Kindler’s plan to take his biotech — which is developing a slate of non-opioid painkillers — public, is back on.

The Boston based company, led by former Pfizer $PFE chief Kindler, originally contemplated a $70 million to $80 million IPO last year— but eventually postponed that strategy. On Wednesday, the company revived its bid to make a public debut in a filing with the SEC — although no pricing details were disclosed.